Related Experiment Videos
Long-term granulocyte-macrophage colony-stimulating factor and immunosuppression in the treatment of acquired severe
J D Hord1, J C Gay, J A Whitlock
1Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2588, USA.
Insights
Granulocyte-macrophage colony-stimulating factor (GM-CSF) combined with immunosuppression effectively treats pediatric severe aplastic anemia (SAA). This combination therapy promotes neutrophil recovery and reduces infection risk in children with SAA.
Area of Science:
- Pediatric Hematology
- Immunosuppressive Therapy
- Hematopoietic Stem Cell Support
Background:
- Acquired severe aplastic anemia (SAA) in children presents a significant challenge, often requiring intensive immunosuppression.
- Neutrophil recovery and infection prevention are critical concerns in managing pediatric SAA.
- The role of colony-stimulating factors in augmenting immunosuppressive therapy for SAA is an area of ongoing research.
Purpose of the Study:
- To evaluate the efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with immunosuppression for treating pediatric SAA.
- To assess GM-CSF's ability to induce sustained neutrophil recovery and reduce infection incidence.
- To determine if GM-CSF enhances the overall therapeutic effectiveness of immunosuppressive regimens in children with SAA.
Main Methods:
- Seven children with newly diagnosed SAA received a 14-day course of intravenous antithymocyte globulin and oral prednisone.
- Long-term daily oral cyclosporine A and subcutaneous GM-CSF (5 micrograms/kg/day) were administered.
- Treatment outcomes were monitored for neutrophil recovery, transfusion independence, and infection rates.
Main Results:
- All seven pediatric patients achieved an absolute neutrophil count > 1.0 x 10(9)/L within 3.5 months.
- Five of six followed patients became transfusion-independent for platelets and red blood cells.
- Patients receiving GM-CSF experienced fewer hospital days and reduced infection incidence compared to historical controls.
Conclusions:
- The addition of GM-CSF to immunosuppressive therapy is beneficial for treating pediatric acquired SAA.
- GM-CSF stimulates granulopoiesis, enhancing neutrophil production in SAA patients.
- This combined approach offers improved protection against infectious complications and supports the efficacy of immunosuppression.
Purpose:
Seven children with newly diagnosed acquired severe aplastic anemia (SAA) were treated with a combination of long-term granulocyte-macrophage colony-stimulating factor (GM-CSF) and immunosuppression to assess the potential for GM-CSF to induce sustained neutrophil recovery, reduce the incidence of infection, and enhance the therapeutic efficacy of immunosuppression.
Methods:
Patients received a 14-day course of i.v. antithymocyte globulin 15 mg/kg/day with oral prednisone 1 mg/kg/day, long-term daily oral cyclosporine A 10 mg/kg/day, and long-term daily s.c. GM-CSF 5 micrograms/kg/day.
Results:
All seven children recovered an absolute neutrophil count of > 1.0 x 10(9)/L within 3.5 months of diagnosis (mean 60 days). Of the six children followed throughout their entire illness (follow-up 10-27 months), five are platelet and red cell transfusion independent (three off-therapy, two on tapering therapy) and one continues on therapy with a diminishing transfusion requirement. Compared with seven children treated previously with immunosuppression alone, children who received GM-CSF spent fewer days in the hospital and were less likely to develop infection.
Conclusions:
The addition of GM-CSF to immunosuppressive therapy appears to be beneficial in the treatment of children with acquired SAA with GM-CSF stimulating granulopoiesis. The children are better protected from infectious complications while immunosuppressive agents achieve full therapeutic potential.